| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Emodinanthrone targets bacterial transport systems. It has been shown to inhibit respiration-driven solute transport at micromolar concentrations in membrane vesicles of Escherichia coli. This suggests that its antibiotic activity may be related to the disruption of energy-dependent transport processes in bacteria. Its role as a precursor to emodin also links it to the biological activities of emodin, which include anti-inflammatory, antioxidant, and anticancer effects.
|
|---|---|
| ln Vitro |
The AknX oxygenase test was conducted using Rhein as a substitute substrate [1].
In vitro, emodinanthrone exhibits antibiotic activity. It inhibits respiration-driven solute transport in E. coli membrane vesicles at micromolar concentrations. This activity is consistent with its role as an anthraquinone precursor. Its potential anticancer properties have also been associated with this compound. As a natural product, it is used to study the biological activities of anthracenones and their derivatives. |
| ln Vivo |
In vivo, emodinanthrone is a precursor of emodin, and it contributes to the biotransformation and therapeutic effects of emodin in vivo. Its biological activities, including laxative and antimicrobial effects, are related to its metabolism to emodin. Specific in vivo studies on emodinanthrone itself are limited, as its primary role is as a metabolic intermediate.
|
| Enzyme Assay |
The biological activities of emodinanthrone are assessed using various in vitro assays. Its antibiotic activity is evaluated using standard antimicrobial susceptibility tests, such as the broth microdilution method, to determine its minimum inhibitory concentration (MIC) against bacterial strains. Its effect on solute transport can be assessed using membrane vesicle assays, where the uptake of radiolabeled substrates is measured.
|
| Cell Assay |
The cellular activity of emodinanthrone is evaluated in bacterial cell cultures. Bacteria are treated with the compound, and its effect on cell growth and viability is measured. Its effect on respiration-driven solute transport can be assessed by measuring the uptake of substrates in the presence of an energy source. Its potential anticancer activity can be evaluated in cancer cell lines using standard cytotoxicity assays.
|
| Animal Protocol |
In animal studies, emodinanthrone is not typically administered directly, as it is primarily a metabolic intermediate. However, its role in the biotransformation of emodin is studied by administering emodin and measuring the levels of emodinanthrone and other metabolites. Its in vivo effects are largely attributed to its conversion to emodin.
|
| ADME/Pharmacokinetics |
Emodinanthrone has a molecular weight of 256.25 g/mol and a chemical formula of C15H12O4. It is a solid with a purity of 98%. It is a natural product belonging to the class of anthracenes. Its solubility and stability are characteristic of anthraquinone derivatives. Detailed pharmacokinetic parameters are not extensively documented in the provided sources.
|
| Toxicity/Toxicokinetics |
Formal toxicology data for emodinanthrone is limited, as it is a research compound. As a natural product, it is generally considered to have a low toxicity profile, but formal toxicology studies have not been conducted. Its use is limited to research applications.
|
| References | |
| Additional Infomation |
Emodin anthrone belongs to the anthrone class of compounds, with the chemical formula anthraquinone-9(10H)-anthrone, containing a methyl group at position 6 and hydroxyl groups at positions 1, 3, and 8. It is an intermediate precursor in the synthesis of hypericin and also a fungal metabolite. It is an anthrone compound belonging to the phenolic class. Emodin anthrone has been reported to exist in peony (Paeonia emodi), sorrel (Rumex acetosa), and rhamnus prinoides, and relevant data are available for reference.
Emodinanthrone (CAS: 491-60-1) is a natural anthracenone and a precursor of the bioactive compound emodin. Its antibiotic activity, demonstrated by its ability to inhibit respiration-driven solute transport in E. coli, makes it a valuable research tool for studying bacterial transport mechanisms and the biological activities of anthraquinone derivatives. It is available from various commercial suppliers for research purposes. |
| Molecular Formula |
C15H12O4
|
|---|---|
| Molecular Weight |
256.25338
|
| Exact Mass |
256.074
|
| CAS # |
491-60-1
|
| PubChem CID |
122635
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.471 g/cm3
|
| Boiling Point |
556.2ºC at 760 mmHg
|
| Melting Point |
254-258 °C(dec.)
|
| Vapour Pressure |
5.6E-13mmHg at 25°C
|
| Index of Refraction |
1.723
|
| LogP |
2.247
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
19
|
| Complexity |
369
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
LAJSXCAVRQXZIO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H12O4/c1-7-2-8-4-9-5-10(16)6-12(18)14(9)15(19)13(8)11(17)3-7/h2-3,5-6,16-18H,4H2,1H3
|
| Chemical Name |
1,3,8-trihydroxy-6-methyl-10H-anthracen-9-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~65.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9024 mL | 19.5122 mL | 39.0244 mL | |
| 5 mM | 0.7805 mL | 3.9024 mL | 7.8049 mL | |
| 10 mM | 0.3902 mL | 1.9512 mL | 3.9024 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
